Brex reports on choosing the right gas card for businesses, highlighting different types, benefits, and key considerations ...

Good morning, and welcome to Paychex's Third Quarter Fiscal 2026 Earnings Call. Participating on the call today are John Gibson and Bob Schrader. [Operator Instructions] As a reminder, this conference ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company’s lead development ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...

Full Year 2025 Revenue of $12.2 Million, up 169% from 2024 Revenue of $2.8 Million for Q4 2025, up 116% from Q4 2024 Gross Profit of $2.3 Million for Q4 2025, a 148% increase from Q4 2024; Gross ...

TD SYNNEX (NYSE: SNX) today announced financial results for the fiscal first quarter ended February 28, 2026.

Senior Prof. Dr. W.I. Siriweera who passed on recently, Was not only a historian of the very highest eminence, But also a trail-blazer of sincerity and forthrightness, For whom double-think and double ...

The world today is in turmoil. The killing of innocent people, the destruction of property, and the spread of hatred among fellow human beings have become distressingly common. Acts of dishonesty- ...

Eaton Vance Tax-Advantaged Dividend Income Fund analysis: 8.31% yield, dividend equities with limited tech exposure, leverage-backed payouts. Click for more on EVT.

Ever wondered why some students consistently score top marks in CBSE board exams while others struggle to go beyond average ...

Introduction: Simple radiofrequency ablation (RFA) is a standard minimally-invasive treatment for lower extremity varicose veins (LEVV), yet concerns regarding recurrence and efficacy in severe cases ...